Valerie Hobson

Turning Point Therapeutics Reports Second-Quarter 2022 Financial Results, Provides Operational Updates

Retrieved on: 
Monday, August 8, 2022
FDA, U.S. Securities and Exchange Commission, ADC, Valerie Hobson, SRC, NDA, CEO, Bristol Myers Squibb, GLOBE, MD Anderson Cancer Center, Population, R, Private Securities Litigation Reform Act, SEC, Investment, Sale, TRK, Achievement, Research, NSCLC, Patient, Therapy, COVID-19, Large-cell lung carcinoma, Cell proliferation, EGFR, Pancreatic cancer, SAN, ROS1, Director, D, Acquisition, Safety, G&A, Turning Point, Form 10-Q, NASDAQ, ALK, Gastrointestinal cancer, BTD, TKI, University, Food and Drug Administration, Security, MET, EML4-ALK positive lung cancer, Pharmaceutical industry, Medical imaging, Vaccine, CSF1R

Announced a definitive merger agreement with Bristol Myers Squibb to acquire Turning Point Therapeutics for $76.00 per share.

Key Points: 
  • Announced a definitive merger agreement with Bristol Myers Squibb to acquire Turning Point Therapeutics for $76.00 per share.
  • The transaction was unanimously approved by both the Bristol Myers Squibb and Turning Point Therapeutics Boards of Directors and is anticipated to close during the third quarter of 2022.
  • The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
  • These forward-looking statements are based upon Turning Point Therapeutics current expectations and involve assumptions that may never materialize or may prove to be incorrect.

Turning Point Therapeutics Announces Pipeline Expansion, Licensing of TPX-4589 (LM-302), A Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate for Gastrointestinal Cancers, From Lanova Medicines

Retrieved on: 
Thursday, May 5, 2022
COVID-19, ADC, MET, TRK, Private Securities Litigation Reform Act, ALK, SRC, NASDAQ, GLOBE, Neoplasm, Annual report, Safety, Pancreatic cancer, Tumor microenvironment, Patient, Partnership, EML4-ALK positive lung cancer, Webcast, Valerie Hobson, Large-cell lung carcinoma, Incidence, Form 10-K, Database, Cell proliferation, GI, Antigen, U.S. Securities and Exchange Commission, INT, SEC, ROS1, CEO, SAN, Gastrointestinal cancer, Therapy, Pharmaceutical industry, CSF1R

SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, announced today that it has entered into an exclusive license agreement with LaNova Medicines Limited (LaNova) to develop and commercialize LM-302, a novel antibody drug conjugate (ADC) targeting Claudin18.2, in the U.S. and rest of the world, excluding Greater China and South Korea. Claudin18.2 is a protein expressed in many gastrointestinal cancers, including gastric, gastroesophageal junction and pancreatic cancer. LM-302, which going forward will be identified as TPX-4589, is currently in Phase 1 clinical trials in both the U.S. and China.

Key Points: 
  • LM-302, which going forward will be identified as TPX-4589, is currently in Phase 1 clinical trials in both the U.S. and China.
  • We are excited to announce our first in-license as a company and strategically expand our clinical stage portfolio, specifically within GI tumors.
  • Claudin18.2 is continuing to emerge as an important target, said Athena Countouriotis, M.D., President and Chief Executive Officer of Turning Point.
  • We are very pleased to partner with Turning Point for LM-302, an innovative drug molecule with the potential as a novel treatment for gastric and pancreatic cancers.

Asymchem and LaNova Medicines Enter into Partnership Agreement, Expanding Biological Capabilities

Retrieved on: 
Thursday, September 16, 2021
Cancer, R, S4 Shanghai–Jinshan Expressway, Efficiency, Drug development, Antibody, Control, G protein-coupled receptor, Patient, Blood, Contract, COO, CDMO, Breast, Solution, ADC, Multimedia, Brain, Partnership, Lung, Valerie Hobson, Fine chemical, Vaccine

The collaboration between Asymchem and LaNovawill include small molecule drugs, monoclonal antibodies, double antibodies, ADC projects and potentially other R&D and production initiatives.

Key Points: 
  • The collaboration between Asymchem and LaNovawill include small molecule drugs, monoclonal antibodies, double antibodies, ADC projects and potentially other R&D and production initiatives.
  • "In the future, we expect to build ADC pilot and commercial production facilities to further enhance Asymchem's capabilities with ADC drugs."
  • Based in Shanghai, LaNova Medicines is a clinical-stage R&D company whose primary focus is the development of macromolecular anti-tumor drugs utilizing GPCRs for monoclonal antibody production.
  • Neither Asymchem nor its subsidiaries assume an obligation to update the forecasts, expectations or statements contained in this release.